Lead-Optimierung
We optimize your lead compounds using expertise and data-driven decisions
The lead optimization stage marks the end of the drug discovery phase and the start of pharmaceutical or biological development. Insight into the absorption, distribution, metabolism, and excretion (ADME) is key to progressing your identified lead compounds after the hit to lead phase.
We support you in the further investigation of their target specificity, pharmacokinetic properties, bioavailability, and safety profiles by offering relevant in vitro and in vivo models, cost-efficient methods, and a key selection of assays using data-driven decision making.
Unser Ansatz
We operate as a unified, committed, accessible team in solving your challenges quickly
Our study directors and technical specialists support you in the selection of your lead compounds with proof of effectiveness, decreased toxicity and absorption properties.
Making use of our portfolio of in vitro and in vivo models combined with in-depth and robust readouts from our state-of-the-art biomarker and imaging equipment, we can apply a data-driven and risk-based approach to this stage of your compound development.
Our team of experts consider your entire development journey when recommending cost-efficient solutions to reach your research milestones. We leverage our network of specialists to reduce your timeline and progress your compound more effectively to the patients that need it most.
Arbeiten Sie mit einem Experten zusammen, um Ihre therapeutischen Forschungsfortschritte voranzutreiben.
Arbeiten Sie mit unserem Team zusammen, um Ihr Medikament und Ihr Zielmolekül im Hinblick auf therapeutische Wirkungen präzise und fachkundig zu bewerten.
Lead Optimization Techniques
InnoSer has experienced and dedicated study directors that manage and guide a proactive and effective study design along with a team of associates and bio technicians to help achieve high-quality service and results. With in-depth knowledge of our models and areas of therapeutic expertise we streamline the selection process to ensure robust results and fast progression. With our in vitro and in vivo facilities, we can support ADME and custom studies with the assessment of lead drug metabolites and relevant biomarkers. Through qualified partners we also offer pharmacometric assessment of lead-compounds. By estimating clinical pharmacokinetics, in-silico, early on in drug development this helps to assess clinical feasibility and reduce risk in your pipeline
We provide the following crucial services that are specific to the progression of your compound into the preclinical phase.
In Vivo Pharmacology
- Early assessment of DMPK properties
- Efficacy
- PK feasibility
- Metabolic stability
- Proof-of-Concept-Studien
- MTD (Maximum Tolerated Dose) determination
- Dose frequency
- Dose response relations
- Therapeutic efficacy in in vivo disease model
In Vivo DMPK
- Assess route of administration
- Bioavailability
- Drug distribution
- DRF (Dose Range Finding)
- Preclinical efficacy
Toxikologie
- Einzeldosis-Toxizität
- Toxizität bei wiederholter Verabreichung
- Toxikokinetik
Biomarker Assessment
-
Custom assay development and validation
- Meso Scale Discovery
- ELISA
- IHC
- Durchflusszytometrie
- High Content Imaging
Imaging capabilities:
With our state-of-the-art equipment we can perform high content cellular imaging which supports compound prioritization and timely decision-making during the hit to lead and lead optimization phases of the drug development project.
Flow cytometry gives us the ability to analyze heterogeneous cell populations at specific time points making it a useful tool for testing drug-cell interactions.
Partnering with us will give you access to Meso Scale Discovery (MSD) testing services ideal for immunogenicity testing and multiplex biomarker assays
Die Pipeline der Arzneimittelentwicklung im Überblick
AAALAC-Akkreditierung
InnoSer hat die AAALAC-Akkreditierung erhalten und damit sein Engagement für einen verantwortungsvollen Umgang mit Tieren unter Beweis gestellt. AAALAC International ist eine gemeinnützige Organisation, die sich durch freiwillige Akkreditierungs- und Bewertungsprogramme für den artgerechten Umgang mit Tieren in der Wissenschaft einsetzt. Die Einrichtungen von InnoSer in den Niederlanden und Belgien sind seit 2016 bzw. 2020 AAALAC-akkreditiert. Weitere Informationen zum AAALAC-Akkreditierungsprogramm finden Sie hier.
Tierschutz
Die 3Rs wirken sich auf alle Bereiche aus, von politischen und regulatorischen Veränderungen bis hin zur Entwicklung und Einführung neuer Technologien und Ansätze. Aus diesem Grund engagiert sich InnoSer kontinuierlich für diese Prozesse und überwacht sie. Die von uns umgesetzten Maßnahmen maximieren unsere Fähigkeit, den Einsatz von Tieren zu ersetzen, zu reduzieren und zu verfeinern, und unterstützen unser Bekenntnis zu diesen Grundsätzen in der Forschung und der Arzneimittelentwicklung.
info@innoserlaboratories.com